Ionis Enac 25 Emerging Insight And Market Forecast

“IONIS ENAC 2.5- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Cystic fibrosis in 7 Major Markets. A detailed picture of the IONIS ENAC 2.5 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.


IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the production of epithelial sodium channel (ENaC) protein in the lung. ENaC is believed to be hyperactive in cystic fibrosis (CF), which is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene. Reduction of ENaC with antisense oligonucleotides (ASOs) in preclinical mouse models of cystic fibrosis lung disease leads to significant decrease of mucus accumulation and inflammation, hallmarks of CF lung disease, and improved lung function. This drug is delivered to the lung via aerosol delivery, which results in broad distribution of ASO in the lung with minimal systemic exposure.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around IONIS ENAC 2.5.
  • The report contains forecasted sales for IONIS ENAC 2.5 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Cystic fibrosis.
  • The report also features the SWOT analysis with analyst insights and key findings of IONIS ENAC 2.5.


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IONIS ENAC 2.5 Analytical Perspective by DelveInsight

  • In-depth IONIS ENAC 2.5 Market Assessment

This report provides a detailed market assessment of IONIS ENAC 2.5 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • IONIS ENAC 2.5 Clinical Assessment

The report provides the clinical trials information of IONIS ENAC 2.5 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Cystic fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence IONIS ENAC 2.5 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Cystic fibrosis are giving market competition to IONIS ENAC 2.5 and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of IONIS ENAC 2.5.
  • Our in-depth analysis of the forecasted sales data of IONIS ENAC 2.5 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IONIS ENAC 2.5. 

Key Questions

  • Which company is developing IONIS ENAC 2.5 along with the phase of the clinical study?
  • What is the technology utilized in the development of IONIS ENAC 2.5?
  • What is the product type, route of administration and mechanism of action of IONIS ENAC 2.5?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IONIS ENAC 2.5 development?
  • What are the key designations that have been granted to IONIS ENAC 2.5?
  • What is the forecasted market scenario of IONIS ENAC 2.5?
  • What is the history of IONIS ENAC 2.5 and what is its future?
  • What is the forecasted sales of IONIS ENAC 2.5 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to IONIS ENAC 2.5?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?


1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Table

Table 1 IONIS ENAC 2.5, Description

Table 2 IONIS ENAC 2.5, Clinical Trial Description

Table 3 IONIS ENAC 2.5, 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figures

Figure 1 The Development Timeline of IONIS ENAC 2.5

Figure 2 Patent Details, IONIS ENAC 2.5

Figure 3 IONIS ENAC 2.5, 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 IONIS ENAC 2.5, US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 IONIS ENAC 2.5, EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 IONIS ENAC 2.5, Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • "IONIS ENAC 2.5
  • IONIS ENAC 2.5 Marketed Drugs Over...
  • IONIS ENAC 2.5 Market Assessment
  • IONIS ENAC 2.5 API Manufacturers/...
  • IONIS ENAC 2.5 US Drug Master File...
  • IONIS ENAC 2.5 Active Substance Ma...
  • IONIS ENAC 2.5 Generic players
  • IONIS ENAC 2.5 Patent Expiration
  • IONIS ENAC 2.5 Patent Exclusivity
  • IONIS ENAC 2.5 API Manufacturers
  • IONIS ENAC 2.5 Global Forecasted S...
  • IONIS ENAC 2.5 API Route of Synthe...
  • IONIS ENAC 2.5 Market sales
  • IONIS ENAC 2.5 SWOT Analysis
  • IONIS ENAC 2.5 Pipeline "

Forward to Friend

Need A Quote